


ACCELERATING ACCESS TO TARGETED THERAPIES




QIAGEN delivers the right test for the right patient at the right time

COMPANION DIAGNOSTICS ACROSS THE FULL WORKFLOW



Unique companion diagnostic offering

Driving the next wave of growth




3 Pharma partnerships

with QIAcuityDx digital PCR

>30 Master collaboration agreements

15 FDA approvals

Oncology CDx approvals



BEYOND A SINGLE TEST: DRIVING LONG-TERM GROWTH



Value creation

Expand the content portfolio
(new assays, biomarkers and applications)

Increase instrument placements

Drive higher testing volumes
greater menu utilization

Strengthen attractiveness as a pharma partner

Driving growth and reinforcing leadership in molecular diagnostics

Why we are positioned to win



Partnerships provide early clinical insights



Technologies positioned ahead of market trends



Positioned for long-term growth

For our **partner**
Enabling better treatment decisions

For our **patients**
Improving treatment outcomes

For **QIAGEN**
Creating long-term value

Case study: Breast cancer



Breast cancer patient journey: From diagnosis to treatment decision

Companion diagnostics

Supporting timely and informed treatment decisions

>2 mn

New breast cancer cases
annually worldwide

Fourth

Largest cause of cancer-
related death globally

70%

Of breast cancers are
ER+/HER2-

Diagnosis

First-line treatment

Disease monitoring

Successful
treatment &
continue
monitoring

Resistance
develops
& clinical
progression

Additional companion diagnostic testing

> Need for rapid and reliable testing

QIAcuity dPCR enables fast and precise biomarker analysis (e.g., ESR1)

- Results in about two hours
- Faster insights to support treatment decisions

✓ Improved experience for
patients and clinicians

✓ Potential to reduce
healthcare costs